[Polyamine evaluation in serum and erythrocytes of pediatric patients with neoplasms].
As previous studies demonstrated, free polyamines (putrescine, spermidine and spermine) are increased in neoplastic tissue and in body fluid (blood, urine and spinal fluid) of patients with tumours in various localization. In pediatric oncology, there aren't many specific markers useful to screen subjects at risk of developing cancer or to follow-up after treatment. For these reasons, polyamines' levels in plasma and erythrocytes have been evaluated in three groups of patients: healthy, with acute leukemia and with solid tumour. Polyamines' content has been determined on samples of blood, previously dansylated, by HPLC (high performance liquid chromatography). The results of this study show that putrescine is decreased in plasma of patients with acute leukemia and with solid tumours. The difference, even if more important in subjects with leukemia, is significant in both groups. Spermidine instead, shows an increase, but only in patients with solid tumour. Erythrocyte assays reveal a significant decrease of spermidine in subjects with acute leukemia with consequent inversion of spermidine/spermine ratio. In erythrocytes there aren't any other significant changes in relation to the levels observed in healthy patients. Polyamine assay, especially that of putrescine and spermidine in plasma, could be propounded as a marker for pediatric neoplasms. Moreover, as it is well-known, pediatric neoplasms lead to alterations of polyamine metabolism, because the synthesis and catabolism of these molecules is closely involved in tumoral growth. Consequently, inhibitors of polyamine synthesis could be used with success in antineoplastic chemotherapy.